Abstract |
The purpose of this review is to analyze clinical evidence about the activity and efficacy of anthracycline-based chemotherapy in metastatic endometrial cancer and to identify the most important preclinical findings that would address future clinical trials. A literature search of published studies was undertaken. Studies were selected by predefined criteria. Clinical trials and preclinical studies were analyzed. The search identified eight phase 3 and 13 phase 2 clinical trials of patients with metastatic endometrial carcinoma treated with an anthracycline-based regimen. The planned dose intensity of the anthracycline had no effect on response rates and survival. Survival increased for patients with a good performance status, and sometimes the duration of responses to anthracycline monotherapy can be very long-lasting. The major findings of anthracycline resistance in preclinical models are reported. Possible future biomarkers targeting mechanisms of anthracycline resistance are suggested, and efforts to define a molecular classification of endometrial cancer are desirable.
|
Authors | Giuseppe Colloca, Antonella Venturino |
Journal | Asia-Pacific journal of clinical oncology
(Asia Pac J Clin Oncol)
Vol. 10
Issue 2
Pg. e75-85
(Jun 2014)
ISSN: 1743-7563 [Electronic] Australia |
PMID | 23176327
(Publication Type: Journal Article, Review)
|
Copyright | © 2012 Wiley Publishing Asia Pty Ltd. |
Chemical References |
|
Topics |
- Anthracyclines
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Endometrial Neoplasms
(drug therapy, pathology)
- Female
- Humans
- Neoplasm Metastasis
- Randomized Controlled Trials as Topic
|